Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ZyVersa Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for ZyVersa Therapeutics, Inc.

ZVSA

ZyVersa Therapeutics, Inc.

About ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for chronic renal and inflammatory diseases. Its platforms include VAR 200, targeting kidney disorders like FSGS and diabetic kidney disease, and IC 100, a monoclonal antibody for inflammatory conditions such as obesity, MS, and neurodegenerative diseases. The company focuses on indication expansion, proprietary technologies, and strategic licensing to address high unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ZyVersa Therapeutics, Inc.

1
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports $1.8 Million Net Loss in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports $25 Million Net Loss and Financial Challenges in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports $19.8 Million Net Loss and Faces Delisting Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports $2.2 Million Net Loss in Q2 2025, Seeks Additional Financing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports $2.3 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports 90% Reduction in Net Losses for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ZyVersa Therapeutics, Inc. ZyVersa Therapeutics Reports Significant Financial Challenges, Decreased Cash Position, and Ongoing Operating Losses in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments